SCHEMBL26690191

SCHEMBL26690191

CCOC(=O)c1ccn2cnc(C)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
KDM4E B2RXH2 9/20 0.43
ALDH1A1 P00352 3/20 0.43
GLA P06280 2/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 2/20 0.43
POLB P06746 2/20 0.43
JMJD6 Q6NYC1 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
NUDT1 P36639 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26413736 0.77 TSHR (0.48) TSHRKDM4EALDH1A1GLAGAA
SCHEMBL26132977 0.75 FNTA (0.49) TSHRKDM4EALDH1A1GLAGAA
SCHEMBL26690222 0.73 KDM4E (0.45) TSHRKDM4EALDH1A1GLAGAA
SCHEMBL9052803 0.73 TSHR (0.58) TSHRKDM4EALDH1A1GLAGAA
SCHEMBL26103520 0.72 JMJD6 (0.45) KDM4EHPGDPOLBJMJD6CA12
SCHEMBL31646944 0.72 GABRG2 (0.46) KDM4EALDH1A1POLBLMNAMAPT
SCHEMBL17729452 0.72 TSHR (0.47) TSHRKDM4EALDH1A1HPGDPOLB
SCHEMBL4719784 0.71 TSHR (0.51) TSHRKDM4EALDH1A1GLAGAA
SCHEMBL24533108 0.71 TSHR (0.46) TSHRKDM4EALDH1A1GLAGAA
SCHEMBL28430134 0.70 CA12 (0.43) TSHRKDM4EALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4526298-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. Hoffmann-La Roche AG (CH) 2025-03-26 EP disclosed
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS HOFFMANN-LA ROCHE INC. (US) 2025-03-06 US disclosed
CN-119212989-A Pyrazole derivatives as STING agonists 豪夫迈·罗氏有限公司 2024-12-27 CN disclosed
WO-2023222644-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2023-11-23 WO disclosed
WO-2023222644-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2023-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS STING1, CGAS, MAVS TSHR 1759/4885KDM4E 2535/4885ALDH1A1 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.